Abstract
Between birth and adulthood, the human gut is colonized by a complex microbial community. Despite established links between the infant gut microbiome and health, knowledge is limited for how complementary feeding influences colonization. Using FoodSeq, an objective DNA-based dietary assessment technique, we analyzed 1,036 fecal samples from 729 children aged 0-3 years across countries in North America, Central America, Africa, and Asia. We detected a wide diversity of 199 unique plant food sequences, of which only eight staple foods were consistently present across all countries. Despite this variation in global diet, we identified universal trajectories in early life dietary exposure: weaning stage, which tracked with dietary diversity, emerged as the dominant dietary signature across populations. Still, dietary diversity did not correlate with gut microbial diversity. Instead, dietary diversity and weaning stage specifically predicted the abundance of adult-like bacterial taxa, including known fiber-degrading taxa, which colonized after age 1. Our findings support a two-stage model of microbiome maturation: an early phase dominated by milk-adapted taxa independent of complementary feeding, followed by a maturation phase where diet shapes adult-like microbiota colonization. This model suggests that tracking and promoting plant dietary diversity may support the timely emergence of an adult-like microbiome.
Competing Interest Statement
Dr. Wayne Shreffler reports personal consultant fees from ALK, Allerfund, Allergy Therapeutics, FARE, Milk Care Co. Mabylon, Novartis, Paraxel, Phylaxis and Third Rock Ventures; Clinical trial agreements with Aravax, DBV, Genentech, Moderna, Novartis, and Regeneron.
Funding Statement
This study was funded by the National Institutes of Health (NIH 5R01DK116187; NIH 5R01DK128611); the Gerber Foundation; the Chan Zuckerberg Initiative; the Burroughs Welcome Fund and Springer Nature
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Duke Health Institutional Review Board of Duke University waived ethical approval for this work under an exemption in the protocol Pro00100567
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
2
Blogs/Media
Author Videos